The ongoing shortage of liraglutide injection and other GLP-1 medications prompted the FDA to prioritize the generic drug applications for these medications in order to improve patient access.
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes ...
Patients who have a family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome Type 2 are not ...
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza ...
The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable for the GLP-1 medication for patients who ...
Liraglutide injection is now approved for adult and pediatric patients ages 10 and up, proving another option amid the GLP-1 ...
The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback